KYOTO -- Takara Bio will ramp up its domestic capacity to produce reagents for PCR tests to 8 million specimens a month, eight times more than the current level, as early as this summer.
Japan government to support drugmaker to prevent supply disruption amid pandemic

Takara Bio will ramp up its domestic capacity to produce reagents for PCR tests to 8 million specimens a month, eight times more than the current level. (Source photos by Shihoko Nakaoka)
KYOTO -- Takara Bio will ramp up its domestic capacity to produce reagents for PCR tests to 8 million specimens a month, eight times more than the current level, as early as this summer.